A REVIEW ON CLINICAL OUTCOMES OF BEMPEDOIC ACID AS ADD-ON THERAPY WITH EZETIMIBE FOR THE TREATMENT OF HYPERLIPIDEMIA

Abstract

Background: Cardiovascular complications are one of the leading causes of global mortality. Statins are intended to produce beneficial effects in reducing the risk of morbidity and mortality in cardiovascular patients. However, it becomes negligible in statin intolerant patients mainly due to muscle related symptoms. Objective: The objective of the study is to summarize the results of the studies available on safety and efficacy of bempedoic acid/ezetimibe combination treatment in statin intolerant patients. Methods: After comprehensive literature survey, in Cochrane Library, PubMed, Embase and Medline, randomized controlled studies involving statin intolerant hyperlipidemia, patients with low- density lipoprotein ≥200 mg/dl and at high risk of cardiovascular disease treated with Bempedoic acid and ezetimibe combination were selected. Results: For final quality analysis two clinical trials were selected to assess the safety and efficacy of the combination of Bempedoic acid and Ezetimibe. Data shows Bempedoic acid and Ezetimibe combination significantly lowered the low-density lipoprotein compared to the control groups (placebo vs Bempedoic acid vs ezetimibe). In addition, the data shows significant reduction in highly sensitive C- reactive protein, non-high density lipoprotein cholesterol, total cholesterol and apolipoprotein B. Conclusion: Overall, we conclude that the combination of Bempedoic acid and Ezetimibe can be considered as a treatment of choice for the treatment of hyperlipidemia for patients with statin-intolerance or maximally tolerated even to low-dose statins.